Oral mucosal immunity and HIV infection: current status
- 4 July 2002
- journal article
- review article
- Published by Wiley in Oral Diseases
- Vol. 8 (s2) , 55-62
- https://doi.org/10.1034/j.1601-0825.2002.00013.x
Abstract
There is a paradox that profound HIV-induced immunodeficiency is present systemically, whereas the majority of infections associated with HIV disease are present or initiated at mucosal surfaces. There is therefore a need to understand both specific and non-specific mechanisms of mucosal protection against HIV and its copathogens. The majority of HIV infections occur as a result of the passage of virus across mucosal membranes. Resistance to HIV infection at mucosal surfaces may be related to HIV-specific CD8+ T cell responses in some individuals and may be the basis for protective vaccine design. However, T-cells, macrophages and dendritic cells in mucosa may be a portal of entry for HIV. Transcytosis of HIV can occur from the mucosal to the submucosal surface and vice versa, and may be inhibited by mucosal immunoglobulins and neutralizing IgA within epithelial cells. HIV-induced alterations to oral epithelial cells, together with impairment of mucosal CD4+ T-cells and consequent altered cytokine secretion, may contribute to secondary infections. It also appears that HIV infection is associated with decreased salivary IgA levels, although a dichotomy between IgA concentrations in saliva and serum has been reported. Mucosal antibody responses, however, seem to be maintained. Considerable attention has been given to the possibility of mucosal immunization against HIV and there is evidence that secretory IgA antibody is neutralizing to different HIV strains. In addition to specific immune factors, it is likely that innate non-specific factors may be significant in protecting mucosal surfaces, including lactoferrin, secretory leukocyte protease inhibitor, mucins, proline rich proteins and cystatins. These may be useful candidate virucides in topical preparations. Thus humoral, cellular and innate immune mechanisms, as well as lymphocyte–epithelial interactions, may all be impaired at mucosal surfaces as a result of HIV infection and may contribute to the susceptibility of mucosa to infective processes.Keywords
This publication has 56 references indexed in Scilit:
- Neutralization of Human Immunodeficiency Virus Type 1 (HIV‐1) Mediated by Parotid IgA of HIV‐1–Infected PatientsThe Journal of Infectious Diseases, 2000
- Secretory Anti–Human Immunodeficiency Virus (HIV) Antibodies in Colostrum and Breast Milk Are Not a Major Determinant of the Protection of Early Postnatal Transmission of HIVThe Journal of Infectious Diseases, 2000
- Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responsesVaccine, 2000
- Mucosal Events in the Pathogenesis of Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 1999
- CD8-suppressor factor and β-chemokine function as a complementary mechanism to cognate immunityImmunology Letters, 1999
- Mucosal HIV InfectionPathobiology, 1998
- Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV‐1Oral Diseases, 1997
- A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.Journal of Clinical Investigation, 1995
- A review: The active peptide of lactoferrinPediatrics International, 1994
- Is there IgA of gut mucosal origin in the serum of HIV1 infected patients?Gut, 1994